Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPW0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,949
Award facts
- Contract value 100% obligated
- $34,948.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,948.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 300 mg/2 mL Xolair (omalizumab) auto-injectors. This firm fixed-price delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to Park Ridge, Illinois, and represents one of numerous delivery orders DMS Pharmaceutical Group has received from DLA's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy established to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The IDC, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, authorizes the company to serve as a critical pharmaceutical supplier for military medical operations globally. DMS Pharmaceutical Group's established performance across diverse therapeutic categories, including specialty biologics and branded pharmaceuticals, demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQPW0?
SPE2DR26FQPW0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FQPW0 worth?
The government has obligated $34,949 on SPE2DR26FQPW0.
Is contract SPE2DR26FQPW0 an order under another contract?
Yes. SPE2DR26FQPW0 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPW0 competed?
The extent of competition for SPE2DR26FQPW0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award